Autolus Therapeutics (AUTL) EBITDA (2017 - 2025)
Historic EBITDA for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$84.9 million.
- Autolus Therapeutics' EBITDA fell 5412.82% to -$84.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$228.8 million, marking a year-over-year increase of 358.44%. This contributed to the annual value of -$220.8 million for FY2024, which is 1126.93% down from last year.
- Per Autolus Therapeutics' latest filing, its EBITDA stood at -$84.9 million for Q3 2025, which was down 5412.82% from -$28.9 million recorded in Q2 2025.
- Over the past 5 years, Autolus Therapeutics' EBITDA peaked at $40.5 million during Q3 2021, and registered a low of -$248.9 million during Q4 2021.
- In the last 5 years, Autolus Therapeutics' EBITDA had a median value of -$52.6 million in 2024 and averaged -$48.2 million.
- As far as peak fluctuations go, Autolus Therapeutics' EBITDA surged by 9265.32% in 2022, and later crashed by 29578.34% in 2023.
- Quarter analysis of 5 years shows Autolus Therapeutics' EBITDA stood at -$248.9 million in 2021, then soared by 92.65% to -$18.3 million in 2022, then crashed by 295.78% to -$72.4 million in 2023, then rose by 22.78% to -$55.9 million in 2024, then tumbled by 51.93% to -$84.9 million in 2025.
- Its last three reported values are -$84.9 million in Q3 2025, -$28.9 million for Q2 2025, and -$59.1 million during Q1 2025.